88876-94-2|RSU 1164|1-(2,3-dimethylaziridin-1-yl)-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol|-范德生物科技公司

RSU 1164

NMR下载 COA and HPLC MSDS下载
names：
1-(2,3-dimethylaziridin-1-yl)-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol
CAS号：
88876-94-2
MDL Number：
MF(分子式)： C10H16N4O3 MW(分子量)： 240.26
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	1-(2,3-dimethylaziridin-1-yl)-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol
英文别名	RSU 1164; RSU-1164; RSU1164;
CAS号	88876-94-2
SMILES	OC(CN1C(C)C1C)CN2C=CN=C2[N+]([O-])=O
Inchi	InChI=1S/C10H16N4O3/c1-7-8(2)13(7)6-9(15)5-12-4-3-11-10(12)14(16)17/h3-4,7-9,15H,5-6H2,1-2H3
InchiKey	VKUQQJFQNDTATQ-UHFFFAOYSA-N
分子式 Formula	C10H16N4O3
分子量 Molecular Weight	240.26
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	RSU 1164(CAS:88876-94-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	RSU 1164 is an electron affinic agent that contain a nitro group together with a weakly basic alkylating aziridine moiety.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Siemann DW. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1115-8. PubMed PMID: 2703392.

[2]Henry JM, Isaacs JT. Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy. J Urol. 1989 Jul;142(1):165-70. PubMed PMID: 2733098.

[3] Hofer KG, Lakkis M, Hofer MG. Cytocidal effects of misonidazole, Ro 03-8799, and RSU-1164 on euoxic and hypoxic BP-8 murine sarcoma cells at normal and elevated temperatures. Cancer. 1989 Apr 15;63(8):1501-8. PubMed PMID: 2924258.

[4] Deacon JM, Holliday SB, Ahmed I, Jenkins TC. Experimental pharmacokinetics of RSU-1069 and its analogues: high tumor/plasma ratios. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1087-90. PubMed PMID: 3755713.

[5] Walling J, Stratford IJ, Adams GE, Stephens MA. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069. Int J Radiat Biol Relat Stud Phys Chem Med. 1988 Apr;53(4):641-9. PubMed PMID: 3258298.

6: Walling JM, Deacon J, Holliday S, Stratford IJ. High uptake of RSU 1069 and its analogues melanotic melanomas. Cancer Chemother Pharmacol. 1989;24(1):28-32. PubMed PMID: 2541936.7: Roizin-Towle L, Pirro JP, Hall EJ. Studies with bifunctional bioreductive drugs. II. Cytotoxicity assayed with A-549 lung carcinoma cells of human origin. Radiat Res. 1990 Oct;124(1 Suppl):S50-5. PubMed PMID: 2236511.8: Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Radiat Res. 1990 Oct;124(1 Suppl):S38-43. PubMed PMID: 2236508.9: Hei TK, He ZY, Piao CQ, Hall EJ. Studies with bifunctional bioreductive drugs. I. In vitro oncogenic transforming potential. Radiat Res. 1990 Oct;124(1 Suppl):S44-9. PubMed PMID: 2236509.10: Siemann DW. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine. Br J Cancer. 1990 Sep;62(3):348-53. PubMed PMID: 2206941; PubMed Central PMCID: PMC1971466.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开